Royal Bank of Canada’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-126,701
| Closed | -$5.1M | – | 7359 |
|
|
2026
Q1 | $5.1M | Buy |
126,701
+38,014
| +43% | +$819K | ﹤0.01% | 2404 |
|
|
2025
Q4 | $2.23M | Sell |
88,687
-57,520
| -39% | -$1.35M | ﹤0.01% | 3061 |
|
|
2025
Q3 | $3.31M | Sell |
146,207
-651,378
| -82% | -$15.2M | ﹤0.01% | 2998 |
|
|
2025
Q2 | $13.8M | Buy |
797,585
+2,650
| +0.3% | +$49.1K | ﹤0.01% | 1794 |
|
|
2025
Q1 | $17.4M | Sell |
794,935
-723,892
| -48% | -$20M | ﹤0.01% | 1389 |
|
|
2024
Q4 | $48.5M | Buy |
1,518,827
+1,376,832
| +970% | +$41.4M | 0.01% | 857 |
|
|
2024
Q3 | $4.1M | Buy |
141,995
+9,034
| +7% | +$335K | ﹤0.01% | 2438 |
|
|
2024
Q2 | $5.1M | Buy |
132,961
+31,627
| +31% | +$1.43M | ﹤0.01% | 2171 |
|
|
2024
Q1 | $5.96M | Sell |
101,334
-16,276
| -14% | -$1.04M | ﹤0.01% | 2047 |
|
|
2023
Q4 | $7.04M | Sell |
117,610
-1,054
| -0.9% | -$53.5K | ﹤0.01% | 1991 |
|
|
2023
Q3 | $4.51M | Sell |
118,664
-21,821
| -16% | -$959K | ﹤0.01% | 2171 |
|
|
2023
Q2 | $12.8M | Buy |
140,485
+3,242
| +2% | +$280K | ﹤0.01% | 1418 |
|
|
2023
Q1 | $9.05M | Buy |
137,243
+33,927
| +33% | +$1.96M | ﹤0.01% | 1628 |
|
|
2022
Q4 | $5.34M | Buy |
103,316
+29,097
| +39% | +$1.54M | ﹤0.01% | 2091 |
|
|
2022
Q3 | $5.07M | Sell |
74,219
-7,953
| -10% | -$471K | ﹤0.01% | 2059 |
|
|
2022
Q2 | $3.72M | Sell |
82,172
-7,610
| -8% | -$347K | ﹤0.01% | 2345 |
|
|
2022
Q1 | $4.56M | Sell |
89,782
-15,408
| -15% | -$680K | ﹤0.01% | 2336 |
|
|
2021
Q4 | $4.97M | Buy |
105,190
+13,309
| +14% | +$524K | ﹤0.01% | 2382 |
|
|
2021
Q3 | $3.03M | Buy |
91,881
+6,232
| +7% | +$350K | ﹤0.01% | 2736 |
|
|
2021
Q2 | $5.41M | Sell |
85,649
-2,124
| -2% | -$110K | ﹤0.01% | 2262 |
|
|
2021
Q1 | $3.77M | Buy |
87,773
+4,104
| +5% | +$194K | ﹤0.01% | 2452 |
|
|
2020
Q4 | $4.79M | Sell |
83,669
-8,396
| -9% | -$355K | ﹤0.01% | 2218 |
|
|
2020
Q3 | $2.78M | Buy |
92,065
+19,568
| +27% | +$585K | ﹤0.01% | 2421 |
|
|
2020
Q2 | $2.37M | Sell |
72,497
-1,785
| -2% | -$57.3K | ﹤0.01% | 2485 |
|
|
2020
Q1 | $1.99M | Sell |
74,282
-2,226
| -3% | -$79K | ﹤0.01% | 2471 |
|
|
2019
Q4 | $2.34M | Sell |
76,508
-87
| -0.1% | -$2.41K | ﹤0.01% | 2749 |
|
|
2019
Q3 | $1.84M | Sell |
76,595
-9,301
| -11% | -$256K | ﹤0.01% | 2820 |
|
|
2019
Q2 | $2.18M | Sell |
85,896
-4,471
| -5% | -$91K | ﹤0.01% | 2687 |
|
|
2019
Q1 | $1.76M | Buy |
90,367
+13,092
| +17% | +$206K | ﹤0.01% | 2798 |
|
|
2018
Q4 | $1.02M | Buy |
77,275
+28,033
| +57% | +$430K | ﹤0.01% | 3146 |
|
|
2018
Q3 | $875K | Buy |
49,242
+43,500
| +758% | +$804K | ﹤0.01% | 3473 |
|
|
2018
Q2 | $127K | Buy |
5,742
+5,740
| +287,000% | +$132K | ﹤0.01% | 4676 |
|
|
2018
Q1 | $0 | Sell |
2
-96
| -98% | -$1.89K | ﹤0.01% | 6311 |
|
|
2017
Q4 | $2K | Buy |
+98
| New | +$1.44K | ﹤0.01% | 6252 |
|
Other funds holding APLS
Royal Bank of Canada's APLS Position: Q2 2026 in Review
Royal Bank of Canada sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 126,701 shares — an estimated $5.1M sold.
Royal Bank of Canada first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $48.5M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Royal Bank of Canada reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Royal Bank of Canada sold 126,701 Apellis Pharmaceuticals shares in Q2 2026, an estimated $5.1M.
- Royal Bank of Canada first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Royal Bank of Canada's Apellis Pharmaceuticals position peaked at $48.5M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.